Abbott to Announce Q1 2026 Financial Results on April 16
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy ABT?
Source: Newsfilter
- Earnings Announcement Schedule: Abbott is set to release its Q1 2026 financial results on April 16 before market open, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings announcement, Abbott will host a conference call at 8 a.m. Central Time (9 a.m. Eastern), allowing investors to engage directly through Abbott's Investor Relations website, enhancing investor interaction.
- Replay Availability: An archived version of the conference call will be made available later that day, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Company Background: Abbott is a global healthcare leader focused on helping people live fully at all stages of life, with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, showcasing its significant impact in the global healthcare market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 104.830
Low
136.00
Averages
148.11
High
169.00
Current: 104.830
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott to Announce Q1 2026 Financial Results on April 16
- Earnings Announcement Schedule: Abbott is set to release its Q1 2026 financial results on April 16 before market open, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings announcement, Abbott will host a conference call at 8 a.m. Central Time (9 a.m. Eastern), allowing investors to engage directly through Abbott's Investor Relations website, enhancing investor interaction.
- Replay Availability: An archived version of the conference call will be made available later that day, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Company Background: Abbott is a global healthcare leader focused on helping people live fully at all stages of life, with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, showcasing its significant impact in the global healthcare market.
See More
Abbott to Announce Q1 2026 Financial Results on April 16
- Earnings Announcement Schedule: Abbott is set to release its Q1 2026 financial results on April 16 before market open, reflecting the company's commitment to transparency and investor communication.
- Live Conference Call: Following the earnings release, Abbott will host a conference call at 8 a.m. Central Time (9 a.m. Eastern), providing an interactive platform for investors to engage with the company's performance.
- Investor Relations Platform: The conference call will be accessible via Abbott's Investor Relations website, ensuring that global investors can easily access the latest information, thereby enhancing the company's image in the capital markets.
- Company Background: Abbott is a global healthcare leader dedicated to helping people live fully at all stages of life, with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines.
See More
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
- Acquisition Completed: Abbott announced the completion of its acquisition of Exact Sciences on March 20, 2026, establishing itself as a leader in the cancer screening and diagnostics sector, which is expected to enhance healthcare access for millions and strategically position the company in a rapidly growing market.
- Market Potential: This transaction allows Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical that is anticipated to elevate the company's already high-single-digit growth expectations and strengthen its competitive edge.
- Expanded Product Portfolio: Abbott now boasts a comprehensive suite of leading cancer early detection products, including the market-leading Cologuard® and Oncotype DX®, which will support personalized treatment decisions and improve patient outcomes and quality of life.
- Future Development Outlook: Following the acquisition, Abbott plans to leverage Exact Sciences' expertise to drive the development of more preventative and personalized diagnostic tools, aiming to optimize treatment decisions and enable earlier cancer detection, thereby enhancing overall health management capabilities.
See More
Abbott Completes Acquisition of Exact Sciences, Enhancing Cancer Diagnostics Leadership
- Acquisition Finalized: Abbott completed the acquisition of Exact Sciences on March 20, 2026, making it a wholly owned subsidiary and marking Abbott's leadership in the rapidly growing cancer screening and diagnostics sector.
- Market Expansion: This transaction positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, which is expected to drive the company towards high-single-digit growth expectations, enhancing its competitive edge.
- Enhanced Product Portfolio: Abbott now boasts a comprehensive suite of products, including Cologuard® and Oncotype DX®, focused on early cancer detection and personalized treatments, significantly strengthening its technological advantage in cancer care.
- Future Growth Potential: Post-acquisition, Abbott plans to leverage Exact Sciences' expertise to develop more preventative and personalized diagnostic tools, aiming to improve treatment outcomes and quality of life for cancer patients.
See More
ABBOTT FINALIZES PURCHASE OF EXACT SCIENCES
- Acquisition Announcement: A company has completed the acquisition of Exact Sciences, enhancing its capabilities in the healthcare sector.
- Strategic Goals: The acquisition aims to leverage Exact Sciences' expertise to improve diagnostic solutions and expand market reach.
- Market Impact: This move is expected to strengthen the company's position in the competitive landscape of medical diagnostics.
- Future Plans: The company plans to integrate Exact Sciences' technologies and resources to drive innovation and growth in its product offerings.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Abbott to Announce Q1 2026 Financial Results on April 16
- Earnings Announcement Schedule: Abbott is set to release its Q1 2026 financial results on April 16 before market open, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings announcement, Abbott will host a conference call at 8 a.m. Central Time (9 a.m. Eastern), allowing investors to engage directly through Abbott's Investor Relations website, enhancing investor interaction.
- Replay Availability: An archived version of the conference call will be made available later that day, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Company Background: Abbott is a global healthcare leader focused on helping people live fully at all stages of life, with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, showcasing its significant impact in the global healthcare market.
See More
Abbott to Announce Q1 2026 Financial Results on April 16
- Earnings Announcement Schedule: Abbott is set to release its Q1 2026 financial results on April 16 before market open, reflecting the company's commitment to transparency and investor communication.
- Live Conference Call: Following the earnings release, Abbott will host a conference call at 8 a.m. Central Time (9 a.m. Eastern), providing an interactive platform for investors to engage with the company's performance.
- Investor Relations Platform: The conference call will be accessible via Abbott's Investor Relations website, ensuring that global investors can easily access the latest information, thereby enhancing the company's image in the capital markets.
- Company Background: Abbott is a global healthcare leader dedicated to helping people live fully at all stages of life, with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines.
See More
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
- Acquisition Completed: Abbott announced the completion of its acquisition of Exact Sciences on March 20, 2026, establishing itself as a leader in the cancer screening and diagnostics sector, which is expected to enhance healthcare access for millions and strategically position the company in a rapidly growing market.
- Market Potential: This transaction allows Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical that is anticipated to elevate the company's already high-single-digit growth expectations and strengthen its competitive edge.
- Expanded Product Portfolio: Abbott now boasts a comprehensive suite of leading cancer early detection products, including the market-leading Cologuard® and Oncotype DX®, which will support personalized treatment decisions and improve patient outcomes and quality of life.
- Future Development Outlook: Following the acquisition, Abbott plans to leverage Exact Sciences' expertise to drive the development of more preventative and personalized diagnostic tools, aiming to optimize treatment decisions and enable earlier cancer detection, thereby enhancing overall health management capabilities.
See More
Abbott Completes Acquisition of Exact Sciences, Enhancing Cancer Diagnostics Leadership
- Acquisition Finalized: Abbott completed the acquisition of Exact Sciences on March 20, 2026, making it a wholly owned subsidiary and marking Abbott's leadership in the rapidly growing cancer screening and diagnostics sector.
- Market Expansion: This transaction positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, which is expected to drive the company towards high-single-digit growth expectations, enhancing its competitive edge.
- Enhanced Product Portfolio: Abbott now boasts a comprehensive suite of products, including Cologuard® and Oncotype DX®, focused on early cancer detection and personalized treatments, significantly strengthening its technological advantage in cancer care.
- Future Growth Potential: Post-acquisition, Abbott plans to leverage Exact Sciences' expertise to develop more preventative and personalized diagnostic tools, aiming to improve treatment outcomes and quality of life for cancer patients.
See More
ABBOTT FINALIZES PURCHASE OF EXACT SCIENCES
- Acquisition Announcement: A company has completed the acquisition of Exact Sciences, enhancing its capabilities in the healthcare sector.
- Strategic Goals: The acquisition aims to leverage Exact Sciences' expertise to improve diagnostic solutions and expand market reach.
- Market Impact: This move is expected to strengthen the company's position in the competitive landscape of medical diagnostics.
- Future Plans: The company plans to integrate Exact Sciences' technologies and resources to drive innovation and growth in its product offerings.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
